Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastati...
Main Authors: | Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-05-01
|
Series: | Cancer Control |
Online Access: | https://doi.org/10.1177/10732748221106267 |
Similar Items
-
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-06-01) -
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
by: Alessandro Rizzo, et al.
Published: (2022-04-01) -
A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment
by: Tomoyo Oguri MD, PhD, et al.
Published: (2021-08-01) -
Prioritization for Plastic Surgery Procedures Aimed to Improve Quality of Life: Moral Considerations
by: Gennaro Selvaggi, MD, PhD, et al.
Published: (2017-08-01) -
Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series
by: Mashiro Okunaka PhD, et al.
Published: (2024-01-01)